<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="89604">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01938612</url>
  </required_header>
  <id_info>
    <org_study_id>D4190C00002</org_study_id>
    <nct_id>NCT01938612</nct_id>
  </id_info>
  <brief_title>A Phase I, Open-Label, Multicentre Study to Evaluate the Safety, Tolerability and Pharmacokinetics of MEDI4736 in Patients With Advanced Solid Tumours</brief_title>
  <official_title>A Phase I, Open-Label, Multicentre Study to Evaluate the Safety, Tolerability and Pharmacokinetics of MEDI4736 in Patients With Advanced Solid Tumours</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase I, open-label, multicentre study of MEDI4736 administered intravenously with
      a standard 3+3 dose-escalation phase to evaluate safety, tolerability, and pharmacokinetics
      in patients with advanced solid tumor followed by an expansion phase in patients with
      advanced solid tumors.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Anticipated">March 2018</completion_date>
  <primary_completion_date type="Anticipated">March 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants experiencing dose-limiting toxicities, adverse events (AEs), serious adverse events (SAEs)</measure>
    <time_frame>90 days after the last dose of MEDI4736</time_frame>
    <description>Safety profile will be assessed through number of participants experiencing adverse events (AEs), serious adverse events (SAEs), laboratory evaluations, vital signs, and physical examinations.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration of MEDI4736 time curve</measure>
    <time_frame>Up to 90 days after the last dose of MEDI4736</time_frame>
    <description>If data allow, noncompartmental PK parameter (AUC) will be estimated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants who developed detectable anti-drug antibodies (ADAs).</measure>
    <time_frame>Up to 6 months after the last dose of MEDI4736 or up to 1 month after the last dose of tremelimumab where applicable.</time_frame>
    <description>The immunogenic potential of MEDI4736 or tremelimumab will be assessed by summarizing the number percentage of subjects who develop detectable anti-drug antibodies (ADAs).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>From first dose of study drug until death or up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum tolerated dose (MTD) or optimal biological dose (OBD)</measure>
    <time_frame>90 days after the last dose of MEDI4736</time_frame>
    <description>maximum tolerated dose (MTD) or optimal biological dose (OBD) of MEDI4736, if possible</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum concentration of MEDI4736</measure>
    <time_frame>Up to 90 days after the last dose of MEDI4736</time_frame>
    <description>If data allow, noncompartmental PK parameter (Cmax) will be estimated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance</measure>
    <time_frame>Up to 90 days after the last dose of MEDI4736</time_frame>
    <description>If data allow, noncompartmental PK parameter (CL) will be estimated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>half-life after administration of MEDI4736</measure>
    <time_frame>Up to 90 days after the last dose of MEDI4736</time_frame>
    <description>If data allow, noncompartmental PK parameter (t½) will be estimated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR)</measure>
    <time_frame>From first dose of study drug until death or up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DoR)</measure>
    <time_frame>From first dose of study drug until death or up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>From first dose of study drug until death or up to 2 years</time_frame>
    <description>Alive and progression free at 6 months (APF6) and 12 months (APF12) will be obtained using the Kaplan-Meier plot of PFS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>From first dose of study drug until death or up to 2 years</time_frame>
    <description>The proportion of patients alive at 12 months will be obtained from the Kaplan-Meier plot of OS.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">240</enrollment>
  <condition>Advanced Solid Tumors</condition>
  <arm_group>
    <arm_group_label>MEDI4736 Q2W</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Evaluate MEDI4736 given every 2 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MEDI4736 Q3W</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Evaluate MEDI4736 given every 3 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MEDI4736 Dose Expansion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>evaluate MEDI4736 given every 2 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MEDI4736 Q4W</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Evaluate MEDI4736 given every 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MEDI4736 combined with another drug</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>evaluate MEDI4736 in combination with another drug given every 4 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MEDI4736</intervention_name>
    <description>MEDI4736 will be administered by IV infusion every 14, 21 or 28 days.</description>
    <arm_group_label>MEDI4736 Q2W</arm_group_label>
    <arm_group_label>MEDI4736 Q3W</arm_group_label>
    <arm_group_label>MEDI4736 Dose Expansion</arm_group_label>
    <arm_group_label>MEDI4736 Q4W</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tremelimumab</intervention_name>
    <description>tremelimumab is administered by IV infusion every 4 weeks</description>
    <arm_group_label>MEDI4736 combined with another drug</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  In the dose-escalation phase: patients with advanced solid tumors refractory to
             standard treatment, intolerant of standard treatment, or for which no standard
             therapy exists.

        In the dose-expansion phase: histologically- or cytologically-confirmed advanced or
        metastatic biliary tract cancer (BTC), esophagus cancer(EC) (squamous cell carcinoma) or
        squamous cell carcinoma of the head and neck (SCCHN). - men or women. - Eastern
        Cooperative Oncology Group (ECOG) status of 0 or 1. - Adequate organ and marrow function.
        - Subjects must have at least 1 measurable lesion. - Available archived tumor tissue
        sample. - Willingness to provide consent for biopsy samples.

        Exclusion Criteria:

          -  Any prior Grade ≥ 3 irAE while receiving immunotherapy - Prior exposure to any
             anti-PD-1 or anti-PD-L1 antibody - Active or prior documented autoimmune disease
             within the past 2 years - History of primary immunodeficiency - Symptomatic or
             untreated central nervous system (CNS) metastases requiring concurrent treatment -
             Women who are pregnant or lactating - Uncontrolled intercurrent illness - Known
             history of tuberculosis - Known to be human immunodeficiency virus (HIV) positive -
             Hepatitis B or C infection - Other invasive malignancy within 5 years
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>130 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Iannone, MD</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Beppu-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chuo-ku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kashiwa-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kitaadachi-gun</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Koto-ku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kure-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Matsuyama-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nagoya-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Osaka-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Osakasayama-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sapporo-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Suita-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sunto-gun</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Takatsuki-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Yokohama-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tainan</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tao-Yuan</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <lastchanged_date>February 10, 2017</lastchanged_date>
  <firstreceived_date>September 5, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>MEDI4736</keyword>
  <keyword>Advanced solid tumors</keyword>
  <keyword>squamous cell carcinoma of the head and Neck</keyword>
  <keyword>biliary tract cancer</keyword>
  <keyword>squamous cell carcinoma of esophagus cancer</keyword>
  <keyword>B7-H1</keyword>
  <keyword>PD-L1</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Tremelimumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
